Crescendo Biologics Limited

Crescendo Biologics Limited is a cutting-edge biotechnology research company focused on developing innovative, targeted T cell enhancing Humabody® therapeutics. Crescendo Biologics is dedicated to pioneering advancements in immuno-oncology, striving to create therapies that offer enhanced efficacy and safety. Their leading product, CB307, is a novel half-life extended CD137 x PSMA Humabody designed for the selective activation of tumor-specific T cells within the tumor microenvironment. Located at Babraham Research Campus, Cambridge, GB, Crescendo Biologics is at the forefront of creating next-generation cancer treatments.

Crescendo Biologics' proprietary pipeline includes CB693, a half-life extended CD137 x MSLN Humabody, and CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. These advancements highlight Crescendo Biologics' commitment to addressing critical needs in cancer therapy through groundbreaking research and development. The company’s unique, patent-protected transgenic mouse platform generates fully human VH domain building blocks (Humabody VH), enabling the creation of multi-functional Humabody therapeutics that deliver novel pharmacology and superior bio-distribution.

With global collaborations with Takeda and BioNTech, and an exclusive agreement with Zai Lab for ZL-1102, Crescendo Biologics is rapidly expanding its reach and impact in the biotechnology sector. Backed by prominent investors, Crescendo Biologics is poised for continued growth and innovation. We invite the manager of Crescendo Biologics Limited to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.